Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05866302 · ClinicalTrials.gov registry record

Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients

A clinical trial of Graft-Versus-Host Disease and Chronic Lung Disease, sponsored by University of Michigan Rogel Cancer Center.

Recruiting
Registry status
375
Enrollment target
6
Study locations

NCT05866302 is a study of Graft-Versus-Host Disease and Chronic Lung Disease that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 375 participants, above the 73-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (414% higher). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05866302, a study of Graft-Versus-Host Disease and Chronic Lung Disease, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.

RECRUITING
Registry status
375 participants
Enrollment target
6
Study locations

Study Summary

The study will have two separate patient cohorts: Cohort 1 will include patients with newly diagnosed chronic graft versus host disease (GVHD), whereas cohort 2 will include patients with newly diagnosed chronic lung disease (CLD). For cohort 1, the primary objective will be to characterize PRM metrics at the onset of chronic GVHD and determine if a PRM signature is present that will predict 1-year CLD free survival. For cohort 2, the primary objective will focus on characterizing PRM at the onset of CLD and determine if PRM can predict the trajectory in lung function decline in affected patients.

Conditions Studied

Graft-Versus-Host Disease Chronic Lung Disease Hematopoietic Cell Transplantation

Study Locations (6)

California

  • Stanford Hospital - Stanford

Georgia

  • Emory University - Atlanta

Massachusetts

  • Dana Farber - Boston

Michigan

  • The University of Michigan Cancer Center - Ann Arbor

Texas

  • MD Anderson - Houston

Washington

  • Fred Hutchinson Cancer Research Center - Seattle

Trial Details

FieldValue
Enrollment Target 375 participants
Start Date 2023-05-30
Est. Completion 2028-05

Sponsor

University of Michigan Rogel Cancer Center

292 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05866302

The ClinicalTrials.gov registry entry for NCT05866302 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 73-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (414% higher). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Graft-Versus-Host Disease appearing as the primary indexed condition, and to 0 interventions.

NCT05866302 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Georgia, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05866302 about?

NCT05866302 is a clinical study titled "Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients". The study will have two separate patient cohorts: Cohort 1 will include patients with newly diagnosed chronic graft versus host disease (GVHD), whereas cohort 2 will include patients with newly diagnosed chronic lung disease (CLD). For cohort 1, the primary objective will be to characterize PRM metr...

What is the current status of trial NCT05866302?

This trial is currently recruiting. The enrollment target is 375 participants. The study started on 2023-05-30. Estimated completion is 2028-05.

What conditions does trial NCT05866302 study?

This clinical trial studies the following conditions: Graft-Versus-Host Disease, Chronic Lung Disease, Hematopoietic Cell Transplantation.

Who is sponsoring clinical trial NCT05866302?

This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05866302 being conducted?

This trial has 6 study locations across California, Georgia, Massachusetts, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Graft-Versus-Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Graft-Versus-Host Disease

All registered trials for this condition

Chronic Lung Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.